Jason Crites

4.8K posts

Jason Crites banner
Jason Crites

Jason Crites

@jasoncrites

Steel Town Kid, Data Nerd, Citizen Scientist, Connecting the world’s data to end human suffering. Founder - Assurance Health Data + GC Media

St Louis, MO Katılım Eylül 2009
5.8K Takip Edilen769 Takipçiler
Jason Crites retweetledi
Mark Cuban
Mark Cuban@mcuban·
Every LLM is a walled garden in a race to beat the hell out of the next foundational model. They all are hoping it’s not like search with one dominant player. They have to invest like it might be. That won’t change for ???? Every enterprise has to keep up with their changing and new models and decide when to move. When to go side by side. When to delete. That’s going to be stressful. And as long as those models don’t truly integrate, and will that ever happen, the amount of work for enterprises to maintain AI and be competitive is going to keep on growing and getting more expensive. And there will be a time when genAI models will be superseded by world view models and who knows what comes after that It’s going to take so many people specializing in various layers and levels of AI In the next 5 years enterprise AI is going to be a mess, with all the different implementations and flavors and sources and models. It’s not inconceivable there can be hundreds of different models in each big enterprise. Just because the company got overwhelmed trying to keep everything tied together. Which in turn could lead very large companies to choose to divest subsidiaries rather than thinking there is benefit from scale. Scale may be a boat anchor to your business. Purely because of AI Curious what everyone thinks ?
Aaron Levie@levie

Whether it’s existing consulting firms, new ones that emerge, FDEs from agent vendors, or new internal agent engineering roles, the amount of work that is going to be created to implement agents in enterprises will exceed anything we imagine today. The complexity of implementing agents in any existing organizations is very real. When I talk to large enterprises, as you move from a chat paradigm to agents that participate in meaningful workflows, there are a number of things they need to do. First, you have to get agents to be able to talk to your data securely across your systems. In many cases, enterprises have decades of legacy infrastructure that contain the valuable context for AI agents. That’s going to take a ton of work to go modernize and move to systems that work well with agents. Then, you need to ensure that you’ve implemented agents with the right access controls and entitlements, the right scopes to be safely used, and have ways of monitoring, logging, and securing the work that they do. Next, you need to actually document the processes in the organization in a way that agents can utilize for doing the work. You also need to figure out what the new workflow looks like when agents and people are working together on a process, and who steps in where. Just replicating the old workflow will mute the gains. Oh and you likely need to create evals for your top new end-state processes. Finally, you have to keep up with a rapidly changing set of best practices and architectural shifts happening in the agent space. While it’s fun for people to change their personal productivity tools on a dime, it’s 100X harder to do this in a business process. The speed of change is a blessing and a curse right now for anyone trying to keep a stable system design. All of this means that individuals and companies that develop expertise on the above set of components (and more) are going to be needed to help organizations actually implement agents at scale. This is also the rationale for vertical AI agents right now that can go in deep on a business domain and help bring automation to it. This is a huge opportunity right now whether you’re doing this internally or as an external business provider.

English
173
52
570
296.6K
Jason Crites retweetledi
Jason Crites retweetledi
TJ Parker⚡️
TJ Parker⚡️@tjparker·
Optimistic take: US healthcare is actually set up very well for the AI era. GP shortage. Best therapies and proceduralists in the world for actual interventions. And a ton of admin bloat / bad incentives that create surface area to arbitrage.
English
15
10
144
12.3K
Jason Crites retweetledi
Star Bar
Star Bar@StarBar_Denver·
@WyattFlores10 @jasoncrites Y’all SLAYED. What a journey. Can’t wait to see this tour. 🌋☄️
English
0
1
2
120
Jason Crites retweetledi
Andrew D. Huberman, Ph.D.
Andrew D. Huberman, Ph.D.@hubermanlab·
So many of my “conventional” (not in the health and wellness space or even online much) MD friends are asking about peptides to 1) get educated (patients are asking them about peptides) 2) they want to know if BPC can help their knee or shoulder or whatever. Wild.
English
76
20
911
249.4K
Jason Crites retweetledi
Wyatt Flores
Wyatt Flores@WyattFlores10·
A show I’ll still be talking about when I’m 80 years old. Until next time Stagecoach ❤️
Wyatt Flores tweet mediaWyatt Flores tweet mediaWyatt Flores tweet mediaWyatt Flores tweet media
English
6
6
122
3.1K
Jason Crites retweetledi
Aakash Gupta
Aakash Gupta@aakashgupta·
Brian Chesky personally photographed every Airbnb listing in New York in 2009. He flew out with a camera, knocked on doors, watched hosts greet strangers, took notes on what felt awkward. Airbnb is now worth $78 billion. His framework was the 11-star experience. A 5-star stay: someone meets you at the door. 6 stars: champagne on arrival. 7 stars: the host pre-stocked your favorite groceries. Keep going. 11 stars: Elon picks you up at the airport in a SpaceX rocket. The exercise sounds ridiculous on purpose. You design the version no one would ever build, then walk it back to what's actually deliverable. The version you ship at the end is a 7. Every competitor ships a 5. Most founders skip this entirely because it doesn't show up in a board deck. There's no metric for "the host left a handwritten welcome note." There's no A/B test for "the apartment smelled clean." Those details compound into something investors call brand and customers call the only company I trust with my kids. Chesky's rule: you don't move to the second user until the first one loves it. You don't move to the millionth until the second one loves it. The hand-crafted phase looks like wasted time on a quarterly review. It's the only phase that creates a real moat. Now look at 2026. The model layer is commoditizing. Every consumer AI app is wrapping the same three labs. Compute is a line item. The thing that decides who survives is whether someone obsessed over what the perfect experience looks like for one specific user before they tried to scale to a million. Cursor did that. Linear did that. Most VC-funded AI products did not. Reverse-engineering an experience to scale takes weeks. Hand-crafting it for one person takes years and looks unproductive the entire time. Most founders refuse to sit in that phase. The few who do end up on the Stanford stage worth $78 billion.
English
4
7
76
19.7K
Jason Crites retweetledi
Wyatt Flores
Wyatt Flores@WyattFlores10·
Whoever the hell stole my stagecoach license plate off the truck backstage…I hope both sides of your pillow are hot forever. We had mayor of Flavortown Guy Fieri himself on tap to hand it out.
English
6
13
379
20.4K
Jason Crites retweetledi
Garry Tan
Garry Tan@garrytan·
Graph, and vector have to work together to get you better retrieval. I realize this is not rocket surgery or new ground— but for it to work out of box with OpenClaw as a Karpathy knowledge wiki synced off a git repo is somewhat useful, and is exactly what I needed for myself
hanzi@hanzi_li

@garrytan this matches what i keep seeing in agent/RAG work: graph, keyword, and vector fail in different ways, so the product win is orchestration + evals, not one retrieval trick. re-embed-on-write is underrated too; stale context is the silent eval killer.

English
13
7
113
20.1K
Jason Crites retweetledi
Jonathan Karl
Jonathan Karl@jonkarl·
. @OzTheMentalist reveals the trick he had just performed on Karoline Leavitt when the shooting happened last night at the White House correspondents’ dinner. He figured out the name of @PressSec ‘s soon to be born child
English
252
839
4.7K
733.1K
Jason Crites retweetledi
Aaron Levie
Aaron Levie@levie·
Great read. AI lets you get tremendous leverage that wasn’t available before in almost any domain. That means we’re at a unique moment in history where anyone with a high level of ambition and core skills in any area can overcome a lot of historical experience requirements for their role. This can apply to anyone who’s junior or senior, but it’s pretty sweet that you can do far more than you could have accomplished as a newer employee than even a couple years ago. The people that take advantage of this will get ahead massively. And the companies that find this talent within or outside should put them in key positions to get as much out of them as possible. These people will seem strange and from the future, but they will help you figure out where things are going. Everyone company should be doing whatever they can to find them.
Jaya Gupta@JayaGup10

x.com/i/article/2047…

English
67
95
911
245.9K
Jason Crites retweetledi
Memorial Sloan Kettering Cancer Center
⚠️ New MSK research presented at #AACR26: A drug given “breakthrough designation” by @US_FDA may offer the best new option in many years for people facing #pancreaticcancer. #Daraxonrasib targets mutations in the RAS gene, which helps control cell growth — these mutations send signals that fuel cancer cells. #KRAS is the most common of these mutations and drives over 90% of pancreatic cancer, which is projected to be the second most deadly cancer in the U.S. by 2030. MSK gastrointestinal medical oncologist @EileenMOReilly led a phase 1/2 clinical trial of daraxonsarib as part of a larger multidisease trial led by thoracic medical oncologist Dr. @KCArbourMD. In Dr. O’Reilly’s trial, the patients with pancreatic cancer had not yet received any form of treatment. “This drug is potentially going to be a landmark shift in how we treat pancreatic cancer,” says Dr. O'Reilly. “The ability to target RAS mutations that drive so much of pancreatic cancer is huge and has been missing from our treatments.” Learn more about this research: bit.ly/4trr1xK @AACR
Memorial Sloan Kettering Cancer Center tweet media
English
1
35
158
13.1K